Immuron announces record Travelen sales globally

Immuron announced record sales of Travelan, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract. Australia: Sales of Travelan increased 236% to AUD $3.7 million for the full financial year to June 2024 compared to AUD $1.1 million for FY23. Sales of Travelan increased 209% to AUD $1.0 million for the June 2024 Quarter compared to AUD $0.3 million for the June 2023 Quarter. Consistent with the increase in June 2024 quarter sales, the Australian Bureau of Statistics reported short term resident returns in April 2024 were 29% higher than April 2023. USa: We achieved a new annual record. The previous highest annual USA sales was AUD $1.0 million in FY19. Sales of Travelan increased 74% to AUD $1.1 million for the full financial year to June 2024 compared to AUD $0.6 million for FY23. Sales of Travelan increased 546% to AUD $0.3 million in the June 2024 Quarter compared to AUD $0.05 million in the June 2023 Quarter. Immuron’s experience in the USA follows the International Trade Administration Total U.S. citizen international visitor departures from the United States in April 2024 being 8% higher than in April 2023.